The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are:

1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD?
2. Do mood symptoms and cognition improve following treatment with vortioxetine?

Researchers will also determine whether there are changes in the brain associated with vortioxetine treatment.

Participants will:

• Undergo a screening visit that involves clinical assessments and laboratory tests
• Undergo an initial brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (18F) Positron Emission Tomography (FDG PET) scan before starting treatment with vortioxetine
• Undergo memory and problem-solving tests before starting treatment with vortioxetine
• Undergo approximately 12 weeks of treatment with vortioxetine, during which time there will be regular contact and assessments with the study psychiatrist
• Undergo a repeat PET scan and repeat memory and problem-solving tests after 12 weeks of treatment with vortioxetine

FTD Patients

Inclusion Criteria:

1. Male or Female
2. Age 45 and above
3. Diagnosis of possible or probable bvFTD based on international consensus criteria for behavioral variant FTD (FTDC)
4. The presence of at least one of the following affective symptoms on the 12-item Neuropsychiatric Inventory: depression, anxiety, irritability, or agitation
5. A global Clinical Dementia Rating (CDR®) plus National Alzheimer's Coordinating Center (NACC) Frontotemporal lobar degeneration (FTLD) Behavior and Language Domains global score (CDR® plus NACC FTLD) less than or equal to one
6. Patients must be medically stable
7. Vortioxetine treatment is clinically indicated
8. Competent to provide informed consent

Exclusion Criteria:

1. No history of drug or alcohol dependence within six months prior to study entry
2. Negative toxicology screening for drugs of abuse
3. Subject must not be pregnant or nursing
4. No contraindications to Vortioxetine treatment
5. No contraindications for Magnetic Resonance (MR) scanning (e.g. metal implanted in the body)

Healthy Controls

Inclusion Criteria:

1. Male or Female
2. Age 45 and above
3. Subjects must be medically stable
4. Free of psychotropic medications
5. Competent to provide informed consent

Exclusion Criteria:

1. No current or past history of neurological or psychiatric illness or substance abuse
2. Subject must not be pregnant or nursing
3. Negative toxicology screening for drugs of abuse
4. No contraindications for MR scanning (e.g. metal implanted in the body)

All de-identified data will be preserved and shared in the National Archive of Computerized Data on Aging (NACDA).

Data will shared 12 months after study starts and every 6 months thereafter. All data will be shared upon publication or at the end of the award period, whichever is sooner. For published studies, data will be shared when the pre- print is available. NACDA studies have digital object identifiers (DOI) to aid in findability. The investigators will include that DOI in relevant publications. NACDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.

Given that all data will be de-identified, the investigators do not plan to control access to the data or require a Data Use Agreement. Data submitted to NACDA that are evaluated as constituting a low disclosure risk are publicly released and available to download directly from the NACDA website. The investigators plan to prepare and submit the data in a de-identified format in order to minimize any disclosure risk and allow for public release through NACDA. NACDA performs an evaluation of all submitted data prior to release to ensure disclosure risks are minimized, and the investigators anticipate approval for public release of data without restriction through the NACDA website.